High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

(2014) Anamarija M. Perry et al.   BRITISH JOURNAL OF HAEMATOLOGY

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

(2013) H. Horn et al.   BLOOD

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients

(2013) Rachel E Culpin et al.   HISTOPATHOLOGY

Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy

(2012) Akiko Miyagi Maeshima et al.   CANCER SCIENCE

Treatment of Diffuse Large B Cell Lymphoma

(2012) Jae-Yong Kwak   KOREAN JOURNAL OF INTERNAL MEDICINE

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2011) G. Gutierrez-Garcia et al.   BLOOD

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

(2011) G. Salles et al.   BLOOD

Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

(2011) Nalan Akyurek et al.   CANCER

BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

(2011) J. Iqbal et al.   CLINICAL CANCER RESEARCH

Topo IIα gene alterations correlated with survival in patients with diffuse large B-cell lymphoma

(2011) Zhenwen Chen et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Distribution of lymphoid neoplasms in the Republic of Korea: Analysis of 5318 cases according to the World Health Organization classification

(2010) Sun Och Yoon et al.   AMERICAN JOURNAL OF HEMATOLOGY

High levels of topoisomerase IIα protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment

(2010) George Pentheroudakis et al.   LEUKEMIA & LYMPHOMA

Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era

(2009) Ritsuko Seki et al.   CANCER SCIENCE

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas

(2009) Heidi Nyman et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP

(2009) Moo-Kon Song et al.   LEUKEMIA & LYMPHOMA

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

(2009) Heidi Nyman et al.   MODERN PATHOLOGY

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

(2008) Darren J. Burgess et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA